Guangzhou Baiyunshan Pharmaceutical's (SHA:600332, HKG:0874) unit, Guangzhou Baiyunshan Tianxin Pharmaceutical, received drug registration certificates from Macao's pharmaceutical regulator for cefazolin sodium for injection, according to a Shanghai bourse filing on Tuesday.
The drug is used to treat infections in the respiratory tract, urinary tract, skin and soft tissues, bones and other parts of the body.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.